Ramesh Rengan MD PhD

Medical Director, Seattle Cancer Care Alliance Proton Therapy Center; Professor of Radiation Oncology, University of Washington School of Medicine; Associate Member, Fred Hutchinson Cancer Research Center

Join to view full profile

1959 NE Pacific StSeattle, WA 98195
Phone+1 206-598-4100

Dr. Rengan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rengan's full profile Already have an account?

Summary

Dr. Rengan is a board-certified radiation oncologist who specializes in radiation treatment for lung, melanoma, and prostate cancer.

Dr. Rengan was previously the Chief of Thoracic Service and Associate Director of Clinical Operations for the Department of Radiation Oncology at the University of Pennsylvania, where he worked extensively with proton therapy. He completed his residency in radiation oncology at Memorial Sloan-Kettering Cancer Center in 2006 and earned his medical degree and Ph.D. in biological chemistry from University of Michigan Medical School and Rackham School of Graduate Studies in 2001.

Dr. Rengan’s philosophy of “patients come first” fits well with his areas of research, which involve the development of clinical and translational (bench-to-bedside) initiatives designed to improve clinical outcomes in cancer. His research interests also include understanding the biology of cancer in order to make radiation treatment more effective and using radiation as a tool to stimulate the immune system to target the cancer.

Education & Training

Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2002 - 2006
UCSF Health – St. Mary’s HospitalInternship, Internal Medicine, 2001 - 2002
University of Michigan Medical SchoolClass of 2001

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2021 - 2027
WA State Medical License 2013 - 2027
PA State Medical License 2006 - 2024
NY State Medical License 2002 - 2015
NJ State Medical License 2006 - 2013
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
COMPLETED
PHASE1, PHASE2
Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy
TERMINATED
PHASE1
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC.
Jing Zeng, Sunan Cui, Daniel S Hippe, Jie Fu, Faisal Yaseen
Clinical Cancer Research. 2026-08-14
Split-Dose FLASH Irradiation to Investigate the Clinical Feasibility of Multifield Treatments: The Effect of Split Dose and Dose Rate on FLASH.
Danielle P Johnson Erickson, Benjamin A Shaver, Clemens Grassberger, Alec Morimoto, Zacharias Seitz
International Journal of Radiation Oncology, Biology, Physics. 2026-04-08
Comparison of integrated biological effectiveness of eye plaques withI andPd photon sources using equivalent uniform RBE-weighted dose.
Yulun He, Kent Wallner, Jonathan J Chen, Ramesh Rengan, Andrew W Stacey
Medical Physics. 2025-12-01

Lectures

Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

What Has Radiology Learned in 5 Years Since COVID Hit U.S.?March 11th, 2025
Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA) Clinicians to Be Featured at the 2021 ASCO Annual MeetingJune 3rd, 2021
Low-Dose Radiotherapy for Lung Inflammation in Severe COVID-19November 5th, 2020

Committees

Committee member, National Cancer Institute’s Radiation and Immune Modulation Working Group
Associate Senior Editor, Journal “Advances in Radiation Oncology."